Pharma BD Deal Intelligence
Voyager Therapeutics enters capsid license agreement and strategic collaboration with Novartis to advance novel gene therapies worth up to $1.3B.
Novartis paid $100 million upfront for access to Voyager's gene therapies for Huntington's disease and SMA.
Partnered Novartis programs for HD, SMA and an undisclosed target continue to advance.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Novartis paid $100M upfront for access to Voyager's gene therapy programs targeting Huntington's disease and spinal muscular atrophy.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Voyager Therapeutics Inc. (this deal) | 2024 | $1.3B | 60 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2024 deals · Novartis AG deals · Gene Therapy deals